CERTAIN INFORMATION IDENTIFIED WITH [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.McDc Base Agreement • May 10th, 2022 • Novavax Inc • Biological products, (no disgnostic substances)
In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 01 hereby amends the Base Agreement as follows:
CHANGE ORDER No. 1Change Order • May 10th, 2022 • Novavax Inc • Biological products, (no disgnostic substances)
This Change Order No.1 (“Change Order”) is made effective as of 31 March 2022 (“Change Order No. 1 Effective Date”) by and between Novavax, Inc., a Delaware corporation having a place of business at 21 Firstfield Rd., Gaithersburg, MD 20878 (“Purchaser”) and SK bioscience Co., Ltd., a company incorporated in the Republic of Korea having a place of business at 310 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13494 Korea (“Supplier”) in accordance with terms and conditions of certain Collaboration and License Agreement dated 12 February, 2021, as amended by the First Amendment to Collaboration and License Agreement dated 23 December, 2021 (“CLA”).
